Lynch Conor P, Cha Elliot D K, Mohan Shruthi, Geoghegan Cara E, Jadczak Caroline N, Singh Kern
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Asian Spine J. 2022 Apr;16(2):195-203. doi: 10.31616/asj.2020.0582. Epub 2021 Jun 17.
Retrospective cohort.
This study aimed to assess the relationship between preoperative narcotic consumption and patient-reported outcomes (PRO) in patients undergoing minimally invasive (MIS) lumbar decompression (LD).
Previous studies report negative effects of narcotic consumption on perioperative outcomes and recovery; however, its impact on quality of life and surgical outcomes is not fully understood.
A surgical database was retrospectively reviewed for patients undergoing primary, single-level MIS LD from 2013 to 2020. Patients lacking preoperative narcotic consumption data were excluded. Demographics, spinal pathologies, and operative characteristics were collected. Patients were grouped based on preoperative narcotic consumption. Patient Health Questionnaire-9 (PHQ-9), Visual Analog Scale (VAS) for back and leg, Oswestry Disability Index (ODI), 12-item Short Form Physical Component Summary, and Patient-Reported Outcomes Measurement Information System physical function (PROMIS-PF) were collected preoperatively and postoperatively. Preestablished values were used to calculate achievement of minimum clinically important difference (MCID). Differences in mean PROs and MCID achievement between groups were evaluated.
The cohort was 453 patients; 184 used preoperative narcotics and 269 did not. Significant differences were found in American Society of Anesthesiologists classification, ethnicity, insurance type, and estimated blood loss between groups. Significant differences were also found in preoperative PHQ-9, VAS leg, ODI, and PROMIS-PF between groups (all p<0.05). Mean postoperative PROs did not differ by group (p>0.05). A higher rate of MCID achievement was associated with the narcotic group for PHQ-9 and PROMIS-PF at 6 weeks (both p≤0.050), VAS leg at 1 year (p=0.009), and overall for ODI and PHQ-9 (both p≤0.050).
Preoperative narcotic consumption was associated with worse preoperative depression, leg pain, disability, and physical function. In patients consuming preoperative narcotics, a higher proportion achieved an overall MCID for disability and depressive symptoms. Patients taking preoperative narcotic medications may report significantly worse preoperative PROs but demonstrate greater improvements in postoperative disability and mental health.
回顾性队列研究。
本研究旨在评估接受微创腰椎减压术(MIS LD)患者术前使用麻醉药品与患者报告结局(PRO)之间的关系。
先前的研究报告了麻醉药品使用对围手术期结局和恢复的负面影响;然而,其对生活质量和手术结局的影响尚未完全了解。
对2013年至2020年接受初次单节段MIS LD手术的患者的手术数据库进行回顾性分析。排除术前缺乏麻醉药品使用数据的患者。收集人口统计学、脊柱病变和手术特征。根据术前麻醉药品使用情况对患者进行分组。术前和术后收集患者健康问卷-9(PHQ-9)、背部和腿部视觉模拟量表(VAS)、Oswestry功能障碍指数(ODI)、12项简短形式身体成分总结以及患者报告结局测量信息系统身体功能(PROMIS-PF)。使用预先确定的值来计算最小临床重要差异(MCID)的达成情况。评估两组之间平均PRO和MCID达成情况的差异。
该队列共有453例患者;184例术前使用麻醉药品,269例未使用。两组之间在美国麻醉医师协会分级、种族、保险类型和估计失血量方面存在显著差异。两组之间术前PHQ-9、腿部VAS、ODI和PROMIS-PF也存在显著差异(均p<0.05)。术后平均PRO在两组之间无差异(p>0.05)。在术后6周时,PHQ-9和PROMIS-PF的MCID达成率较高与麻醉药品组相关(均p≤0.050),术后1年腿部VAS的MCID达成率较高与麻醉药品组相关(p=0.009),ODI和PHQ-9总体上的MCID达成率较高与麻醉药品组相关(均p≤0.050)。
术前使用麻醉药品与术前更严重的抑郁、腿痛、功能障碍和身体功能相关。在术前使用麻醉药品的患者中,更高比例的患者在功能障碍和抑郁症状方面总体上达成了MCID。术前服用麻醉药品的患者术前PRO可能显著更差,但术后功能障碍和心理健康状况改善更大。